Does EGPA Cause Chronic Fatigue Even When in Remission?
At a Glance
Yes. Fatigue can continue during EGPA remission because remission controls the main blood-vessel inflammation but may not resolve asthma, sinus disease, medication effects, previous organ damage, poor sleep, or other treatable causes. New or worsening symptoms need medical review.
Many people with Eosinophilic Granulomatosis with Polyangiitis (EGPA) feel frustrated when their doctor says some tests look reassuring, yet they still feel completely exhausted. If your eosinophil levels are normal but you are dealing with chronic fatigue, your experience is completely valid. Fatigue is frequently reported in EGPA, and it can persist even when your systemic disease is considered to be in “clinical remission” [1][2].
Normal eosinophil counts are certainly good news, but they do not always tell the whole story. Clinical remission is not based on a single blood test; it requires a comprehensive assessment of your symptoms, physical exam, and overall organ function [3]. Research shows that medications like glucocorticoids (steroids) or targeted biologic therapies can suppress eosinophil levels into the normal range even if underlying disease activity remains [4][5]. Furthermore, persistent fatigue by itself does not automatically mean your active EGPA has returned.
What Does Remission Actually Mean?
Remission in EGPA generally means the systemic vasculitis (widespread inflammation of the blood vessels) appears controlled. However, remission is not always a complete cure. You may still experience localized inflammation (like asthma) or symptoms from accumulated organ damage that persist independently of the active vasculitis [6][2].
Why Am I Still So Tired?
1. Persistent Airway and Sinus Symptoms
Even when the systemic vasculitis is controlled, many patients still experience active asthma or chronic sinus issues like nasal polyps [6]. Studies show that this localized airway inflammation can severely impact a patient’s overall quality of life and disrupt their sleep, leading to deep daytime exhaustion [2][1].
2. The Impact of Medications and Tapering
The medications used to control EGPA are a major source of fatigue. Long-term use of glucocorticoids can cause disrupted sleep, metabolic changes, and steroid myopathy [7][8]. Unlike general exhaustion, steroid myopathy typically causes painless weakness in your proximal muscles—you might notice difficulty rising from a chair, climbing stairs, or lifting your arms.
Additionally, if your doctor is lowering (tapering) your steroid dose, new or worsening fatigue should not be ignored. It may indicate an EGPA relapse or a condition called adrenal insufficiency, where your body struggles to restart its own natural steroid production [7].
3. Residual Organ Damage
EGPA can cause damage to tissues that takes a long time to heal or may be permanent. Peripheral neuropathy (nerve damage causing pain, numbness, or weakness) frequently persists even after remission, draining both physical and mental energy [9][10]. Additionally, EGPA can sometimes affect the heart, which can cause fatigue and reduced exercise tolerance [11][12]. However, not every patient needs advanced cardiac imaging; your doctor will determine the need for an electrocardiogram (ECG), echocardiogram, or cardiac MRI based on your specific history and symptoms [11].
4. Other Common Medical Causes
Because EGPA is a complex disease, it is easy to blame every symptom on it. However, your fatigue might be caused by everyday, treatable conditions such as anemia, iron deficiency, thyroid disease, infections, sleep apnea, or simply physical deconditioning from being ill. Your doctor will likely want to rule these out.
5. The Mental and Emotional Toll
Living with a rare, chronic illness is exhausting. The constant vigilance and the anxiety of potential relapses take a heavy psychological toll. Depression, anxiety, and poor sleep are major contributors to fatigue and deserve proper screening and treatment [2]. However, new physical symptoms should never be automatically dismissed as “just stress” without a proper medical evaluation.
When to Seek Urgent Help
Do not stop or rapidly reduce your steroid medications on your own, as this can be dangerous [7]. Seek immediate medical attention if you experience:
- Severe dizziness, fainting, or confusion
- Vomiting or the inability to keep your steroid medication down
- New or rapidly worsening chest pain or shortness of breath
- New significant neurologic weakness, such as suddenly dragging a foot (foot drop)
Next Steps: What You Can Do
Because fatigue in EGPA has multiple potential causes, it requires a comprehensive approach. Track your symptoms—including sleep quality, exactly when you feel tired, and any changes in your medication doses—and use the questions on this page to prepare for a structured conversation with your doctor.
Common questions in this guide
Can I still have severe fatigue if my EGPA is in remission?
Do normal eosinophil levels prove that my EGPA is inactive?
Can EGPA medicines or a steroid taper make me tired?
What other problems can cause fatigue during EGPA remission?
Could my heart be causing fatigue if I have EGPA?
When is fatigue with EGPA an emergency?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.How are you defining remission in my case, and what is our plan for evaluating my fatigue now that my eosinophils are normal?
- 2.Could my current dose of steroids, or the tapering process, be contributing to my fatigue or causing muscle weakness?
- 3.My asthma and sinus issues still disrupt my sleep. What targeted therapies could we explore to improve my airway symptoms without increasing my systemic steroids?
- 4.Based on my history and current symptoms, do we need to check for silent organ involvement, such as an ECG or echocardiogram for my heart?
- 5.Who should I contact and what should I do if my exhaustion worsens suddenly, especially during a steroid taper?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (12)
- 1
Eosinophilic granulomatosis with polyangiitis: sequential use of mepolizumab following rituximab for inadequate asthma control despite vasculitis remission.
Cremonezi Lammoglia B, De Aguiar Trevise L, Paslar Leal T, et al.
Reumatismo 2023; (75(4)) doi:10.4081/reumatismo.2023.1588.
PMID: 38115776 - 2
Focus on the Involvement of the Nose and Paranasal Sinuses in Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss Syndrome): Nasal Cytology Reveals Infiltration of Eosinophils as a Very Common Feature.
Seccia V, Baldini C, Latorre M, et al.
International archives of allergy and immunology 2018; (175(1-2)):61-69 doi:10.1159/000484602.
PMID: 29393242 - 3
Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management.
Groh M, Pagnoux C, Baldini C, et al.
European journal of internal medicine 2015; (26(7)):545-53.
PMID: 25971154 - 4
Serum biomarkers in patients with relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss).
Dejaco C, Oppl B, Monach P, et al.
PloS one 2015; (10(3)):e0121737 doi:10.1371/journal.pone.0121737.
PMID: 25812008 - 5
Refractory diffuse alveolar hemorrhage caused by eosinophilic granulomatosis with polyangiitis in the absence of elevated biomarkers treated successfully by rituximab and mepolizumab: A case report.
Shiroshita A, Nakashima K, Motojima S, Aoshima M
Respiratory medicine case reports 2019; (26()):112-114 doi:10.1016/j.rmcr.2018.12.010.
PMID: 30603598 - 6
Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis.
Teixeira V, Mohammad AJ, Jones RB, et al.
RMD open 2019; (5(1)):e000905 doi:10.1136/rmdopen-2019-000905.
PMID: 31245051 - 7
Optimal therapy and prospects for new medicines in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).
Pagnoux C, Groh M
Expert review of clinical immunology 2016; (12(10)):1059-67 doi:10.1080/1744666X.2016.1191352.
PMID: 27191665 - 8
Eosinophilic granulomatosis with polyangiitis: case report and literature review.
Alam V, Nanzer AM
Breathe (Sheffield, England) 2022; (18(4)):220170 doi:10.1183/20734735.0170-2022.
PMID: 36865937 - 9
Intravenous immunoglobulin for chronic residual peripheral neuropathy in eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome): a multicenter, double-blind trial.
Koike H, Akiyama K, Saito T, et al.
Journal of neurology 2015; (262(3)):752-9 doi:10.1007/s00415-014-7618-y.
PMID: 25577176 - 10
Successful Treatment of Eosinophilic Granulomatosis With Polyangiitis: A Case of Refractory Peripheral Neuropathy and Comorbid Chronic Progressive Pulmonary Aspergillosis Treated With Mepolizumab.
Sekiya R, Soma T, Nakagome K, Nagata M
Cureus 2024; (16(1)):e52192 doi:10.7759/cureus.52192.
PMID: 38222984 - 11
[Cardiac involvement in Churg-Strauss syndrome].
Brucato A, Maestroni S, Masciocco G, et al.
Giornale italiano di cardiologia (2006) 2015; (16(9)):493-500 doi:10.1714/1988.21524.
PMID: 26418389 - 12
Cardiac involvement in eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome): Prospective evaluation at a tertiary referral centre.
Zampieri M, Emmi G, Beltrami M, et al.
European journal of internal medicine 2021; (85()):68-79 doi:10.1016/j.ejim.2020.12.008.
PMID: 33358337
This page explains possible causes of fatigue during EGPA remission for informational purposes only and does not constitute medical advice. Do not stop or change steroid treatment without speaking with your healthcare team.
Get notified when new evidence is published on Eosinophilic granulomatosis with polyangiitis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.